Skip to main content
Frontiers in Cellular Neuroscience logoLink to Frontiers in Cellular Neuroscience
. 2013 Oct 11;7:180. doi: 10.3389/fncel.2013.00180

Prenatal serotonin reuptake inhibitor (SRI) antidepressant exposure and serotonin transporter promoter genotype (SLC6A4) influence executive functions at 6 years of age

Whitney M Weikum 1, Ursula Brain 1, Cecil M Y Chau 1, Ruth E Grunau 1, W Thomas Boyce 1, Adele Diamond 2, Tim F Oberlander 1,*
PMCID: PMC3795328  PMID: 24130516

Abstract

Prenatal exposure to serotonin reuptake inhibitor (SRI) antidepressants and maternal depression may affect prefrontal cognitive skills (executive functions; EFs) including self-control, working memory and cognitive flexibility. We examined long-term effects of prenatal SRI exposure on EFs to determine whether effects are moderated by maternal mood and/or genetic variations in SLC6A4 (a gene that codes for the serotonin transporter [5-HTT] central to the regulation of synaptic serotonin levels and behavior). Children who were exposed to SRIs prenatally (SRI-exposed N = 26) and non-exposed (N = 38) were studied at age 6 years (M = 6.3; SD = 0.5) using the Hearts & Flowers task (H&F) to assess EFs. Maternal mood was measured during pregnancy (3rd trimester) and when the child was age 6 years (Hamilton Depression Scale). Parent reports of child behavior were also obtained (MacArthur Health & Behavior Questionnaire). Parents of prenatally SRI-exposed children reported fewer child externalizing and inattentive (ADHD) behaviors. Generalized estimate equation modeling showed a significant 3-way interaction between prenatal SRI exposure, SLC6A4 variant, and maternal mood at the 6-year time-point on H&F accuracy. For prenatally SRI-exposed children, regardless of maternal mood, the H&F accuracy of children with reduced 5HTT expression (a short [S] allele) remained stable. Even with increasing maternal depressive symptoms (though all below clinical threshold), EFs of children with at least one short allele were comparable to children with the same genotype whose mothers reported few if any depressive symptoms—in this sense they showed resilience. Children with two long (L) alleles were more sensitive to context. When their mothers had few depressive symptoms, LL children showed extremely good EF performance—better than any other group. When their mothers reported more depressive symptoms, LL children's EF performance was worse than that of any other group. In the face of a mother with a more depressed mood, EFs were best preserved in children prenatally exposed to SRIs and with at least one short SLC6A4 allele. Yet, prenatally-exposed LL children hold out promise of possibly superior EF if their mother's mood remains euthymic or improves.

Keywords: serotonin, executive function, childhood, prenatal exposure, SRI, SLC6A4 genotype, depression

Introduction

Serotonin (5-HT) and its multiple receptors are highly expressed in prefrontal cortex (PFC) and play key roles in influencing complex cognition and resilience to stress (Canli et al., 2005; Lesch, 2007; Reuter et al., 2007; Homberg and Lesch, 2011). Dense projections of 5-HT neurons into prefrontal regions (Preece et al., 2004), and a wide distribution of 5-HT receptors and 5-HT transporter sites in PFC (Varnäs et al., 2004) contribute to 5-HT's role in cognition (King et al., 2008). Critical cognitive capacities that rely on PFC and related structures (Miller and Cohen, 2001; Braver et al., 2002; Petrides, 2005; Champod and Petrides, 2007; Zanto et al., 2011) are termed executive functions (EFs), and include abilities to (1) focus, sustain and shift attention (executive attention), (2) resist the pulls and temptations of external stimuli, our emotions, or engrained behavioral tendencies, inhibit acting impulsively, taking a moment to make a more considered response (inhibitory control), (3) hold information in mind and work with it, such as updating one's thinking or planning when given new information, considering alternatives, or mentally relating pieces of information to one other (working memory), and (4) creative problem-solving, flexibly adjusting to changed demands, priorities, new obstacles or opportunities (cognitive flexibility; Miyake et al., 2000; Diamond, 2013). Not surprisingly, good EFs are critical for all aspects of life, including mental and physical health and success in school and in life (Moffitt et al., 2011; Diamond, 2013). For example, childhood EFs predict school readiness and success in math and reading throughout all school years from kindergarten through university better than does IQ, even when controlling for SES (Bull and Scerif, 2001; Blair, 2002; Riggs et al., 2004; Blair et al., 2005; Gathercole et al., 2005; Blair and Razza, 2007).

5-HT plays a critical role in brain development (Kalueff et al., 2010; Olivier et al., 2011). In animal models, developmental shifts in central 5-HT signaling shape early cognitive capacities setting pathways for learning and behavior later in life (see for review Kalueff et al., 2010). Little, however, is known about how developmental changes in 5-HT influence early cognitive development in humans during childhood.

The increasing use of serotonin reuptake inhibitor (SRI) antidepressants to manage maternal mood disorders during pregnancy (Cooper et al., 2007) raises critical questions about the impact of prenatal altered central 5-HT levels on the development of systems that regulate attention, working memory, and self-control (i.e., EFs) in childhood (Kalueff et al., 2010; Hanley and Oberlander, 2012). SRIs primarily act by blocking reuptake of serotonin transporter protein (5-HTT), thereby increasing how much, and how long, extracellular 5-HT remains active and available. SRIs readily cross the placenta and the blood-brain barrier (Kim et al., 2006) altering fetal central 5-HT levels (Laine et al., 2003). Prenatal SRI exposure affects (1) fetal (Salisbury et al., 2009; Mulder et al., 2011) and newborn neurobehavior (Moses-Kolko et al., 2005), (2) neonatal stress regulation (Oberlander et al., 2002, 2005), (3) shifts language perception during the first year of life (Weikum et al., 2012), and (4) is associated with emotional regulation in toddlers (Oberlander et al., 2010).

Why some, but not all, children are affected by prenatal SRI exposure is still a central and pressing question (Hanley and Oberlander, 2012). In the early school years prenatally exposed children appear to have typical language development, behavior and IQ (Nulman et al., 2002). However, not all outcomes can be specifically attributed to prenatal antidepressant exposure. Distinguishing the concurrent impact of pre and postnatal maternal mood disturbances remains challenging (Oberlander et al., 2010).

The pre-synaptic membrane-bound serotonin transporter protein (5-HTT)—the very target of SRI antidepressants—is central to the regulation of intra-synaptic 5-HT. Allelic variations in 5-HTTLPR (SLC6A4) influences gene transcription and the amount of 5-HT available at postsynaptic sites (Lesch et al., 1996). The short (S) variant is associated with reduced gene transcription and reduced levels of 5-HTT protein, with an ~50% reduction in 5-HT reuptake compared to the long (L) variant (Heils et al., 1996; Homberg et al., 2007a). Reduced 5-HTT protein availability and 5-HT reuptake results in a higher effective “serotonin dose.”

Homozygosity for the short (S) allele is associated with increased stress sensitivity and risk for emotional disturbances including anxiety and depression but better EFs (not unlike what has been found for the COMT- MET genotype (Goldman et al., 2005; Diamond, 2011). In combination with early life stressors, the short allele has been widely studied as an important risk factor for mental illness later in life (Caspi et al., 2003; Kendler et al., 2005; Lesch, 2007). For example, adolescents who encountered adversity in childhood and are homozygous for the short allele of 5-HTTLPR have a heightened sensitivity to potential negativity and threat in the environment and are more prone to anxiety and depression (Owens et al., 2012). In animal models, increased 5-HT levels secondary to 5-HTT blockade at developmentally sensitive time periods (akin to a human 3rd trimester) causes permanent axonal connection deficits in the somatosensory cortex (Homberg et al., 2010), the lateral geniculate nucleus (Gaspar et al., 2003), and altered neuronal dendritic branching, elongation and pruning (Homberg et al., 2010; Liao and Lee, 2011; Olivier et al., 2011; Simpson et al., 2011; Zheng et al., 2011). Beyond the newborn period, SRI-exposed animals demonstrate decreased 5-HT levels—possibly via prolonged activation of inhibitory receptors (i.e., 5-HT1a; Hensler, 2006). This might underlie the reduced novelty investigation, poorer motor performance (Lee and Lee, 2012), increased anxiety in conflict tasks and anhedonia (Ansorge et al., 2004, 2008; Popa et al., 2008) reported in fluoxetine-exposed mice. Adults with two short 5-HTTLPR alleles consistently outperform those with one or two long alleles on measures of EFs such as the Wisconsin Card Sorting test (Borg et al., 2009) and go/no-go tests (Roiser et al., 2007), they also show brain patterns consistent with better EFs (Enge et al., 2011). Conversely, the L-allele of the 5-HTTLPR gene is associated with poor EFs including impulsivity, inattention, and working memory deficits (see the meta-analysis by Gizer et al., 2009). Together these findings support the notion that changes in transcriptional activity associated with allelic variations in the 5-HTTLPR gene and presumably reflecting alterations in central serotonin levels, influence EFs in the mature adult brain.

Beyond genetic variations, experimental manipulations of central serotonin levels in adults also appears to affect cognitive functions. Acute SRI administration to healthy adults has been shown to improve verbal fluency, a measure of EFs requiring memory of words, inhibitory control to avoid repeating words, and cognitive flexibility to switch to different paths and strategies for coming up with words (Schmitt et al., 2001). Although reduced 5-HT, using an acute tryptophan depletion (ATD) model with healthy volunteers, has been found to improve focused attention (Schmitt et al., 2000; Evers et al., 2006), enhanced EF performance and reduced impulsivity have also been found in some animal models of SRI exposure (e.g., Sasaki-Adams and Kelley, 2001) but not all (e.g., Valluzzi and Chan, 2007). Importantly, 5-HTTLPR genotype and SRI exposure do not affect, or inconsistently affect, non-EF cognitive abilities such as recall and recognition memory and mental rotation (e.g., 5-HTTLPR genotype: Roiser et al., 2006; Mannie et al., 2009, SRI exposure: Harmer et al., 2002; Siepmann et al., 2003; Riedel et al., 2005).

An acute pharmacological exposure to an SRI or dietary depletion of tryptophan in a mature brain may not result in the same consequences as chronic prenatal SRI exposure and the associated long-term changes in prenatal 5-HT signaling that occurs with such exposure across developmentally sensitive periods of brain growth (Ansorge et al., 2004). To date, studies focusing on the effects of prenatal SRI exposure have typically sought to examine the consequences of what is generally considered increased developmental serotonergic tone. However, in humans the developmental course or behavioral consequences that might follow prenatal SRI exposure (i.e., downstream lower serotonergic tone) is not known. Given the developmental role of 5-HT, it is conceivable that prenatal changes in 5-HT either via genetic variations or prenatal SRI exposure might influence early cognitive development in humans.

To further understand the developmental impact of prenatal SRI exposure on early cognitive development, we studied whether prenatal exposure to SRI antidepressants or maternal mood affects core cognitive skills (EFs) in early childhood, controlling for prenatal maternal mood. Secondarily, we also sought to examine whether changes in EFs are moderated by the child's SLC6A4 genotype, reflecting genetic variations in the capacity to control serotonergic tone that may influence the impact of exposure to maternal mood or SRIs. Given fetal changes in 5-HT signaling secondary to prenatal SRI exposure, and the literature showing improved cognitive function among S carriers, we expected that antidepressant exposure and reduced SLC6A4 transcription (at least one short [S] allele) at a developmentally sensitive time (i.e., in utero) would be associated with improved EF capacity in early childhood, while elevated maternal depressive symptoms would have an opposing effect at 6 years of age.

Materials and methods

Participants

Children in this study are part of a longitudinal cohort study examining the effects of prenatal exposure to SRIs and maternal mood disturbances in 98 mothers recruited during their second trimester of pregnancy. Approval was obtained from the University of British Columbia Ethics Board and the Children's and Women's Health Centre of British Columbia Research Review Committee. Written informed parental consent was obtained to follow the development of these children. All mothers, regardless of their mood or medication status, were physician-referred or self-referred from the Reproductive Mental Health Clinic at British Columbia Women's Hospital and Health Centre (a tertiary-care service), community midwife clinics or family physician practices in the greater Vancouver metropolitan area. All SRI-treated mothers had started taking medications based on clinical need, had a diagnosis of a mood disorder, and were already taking antidepressant medications at the time of conception. Women in the non-SRI group had a range of mood symptoms at the time of recruitment as assessed by the Hamilton Rating Scale for Depression (HAM-D; see Table 1). Of the original 98 mothers, 4 withdrew before the baby was born and another 4 withdrew before the end of the child's first year. At 6 years, an additional 26 children were unavailable for study (22 families had moved and 4 mothers had withdrawn by 3 years). At the time of this study, 64 children (26 prenatally SRI-exposed and 38 non-exposed) were seen at mean age 6.3 years (SD = 0.51 years). From this sample, 25 exposed and 32 non-exposed had both prenatal maternal mood scores and samples of the child's blood available for genotyping.

Table 1.

Maternal characteristics.

Non-exposed (n = 38) SRI-exposed (n = 26) T p-value
Prenatal HamA (mean) (SD) (n = 35 non-exposed and 25 SRI-exposed) 5.5 (4.75) 9.58 (6.75) −2.8 0.007
Prenatal HamD (mean) (SD) (n = 34 non-exposed and 25 SRI-exposed) 3.64 (4.26) 8.54 (6.28) −3.66 0.001
Maternal smoking during pregnancy 0 0 0
Maternal alcohol consumption (drinks in pregnancy) (n = 37 non-exposed) 2.49 (4.49) 3.69 (8.35) −0.74 0.462
Maternal age at birth (years) 33.21 (4.93) 31.42 (4.6) 1.45 0.151
Maternal education (years) 17.8 (2.71) 15.27 (2.39) 3.83 0.001
MATERNAL SLC6A4 GENOTYPE (n's)
LL 10 7 0.704
1S 27 18

Child mental health symptomatology

Measures of child mood and behavior were obtained from the mental health symptomatology section of the MacArthur Health and Behavior Questionnaire (HBQ; Boyce et al., 2002; Essex et al., 2002) that was completed by maternal report (HBQ-P) and yielded measures of internalizing, externalizing and Attention-Deficit and Hyperactivity Disorder (ADHD) behaviors for each child. The HBQ was derived from the Ontario Child Health Study measure designed to map onto DSM-III-R symptom criteria (Boyle et al., 1993). The HBQ-P has strong psychometric properties and has been used to assess child mental health across multiple ages from 4.5 years into adolescence (Ablow et al., 1999; Essex et al., 2006; Shirtcliff and Essex, 2008) The mental health scales have been shown to discriminate groups of children with and without signs of early psychopathology (Luby et al., 2002).

The HBQ-P, administered in questionnaire format, assesses symptoms ranging from “never or not true” to “often or very true.” Symptoms in three domains were analyzed: (1) ADHD symptoms consist of items indexing inattention, impulsivity, and hyperactivity. (2) Externalizing symptoms consist of items indexing oppositional defiant behaviors and conduct problems. (3) Internalizing symptoms consist of items indexing symptoms of depression, separation anxiety, and generalized anxiety. In addition to mean symptom level, the percentage of children above clinical cutoffs was examined. Clinical cutoffs for parent reported ADHD, externalizing, and internalizing symptoms (1.2, 0.68, 0.71, respectively) were set based on previous analysis of the HBQ-P (Lemery-Chalfant et al., 2007) with children of approximately the same age as in the present study.

EF tasks

EFs were assessed using the H&F task, a computerized measure that has been validated with children 4–13 years of age and with adults (Davidson et al., 2006; Diamond et al., 2007). This task assesses inhibition, working memory and cognitive flexibility. A stimulus appears to the right or left of a computer screen on every trial. On Block 1 of the task (the congruent block), participants have only to do what comes naturally (i.e., pressing on the same side as the stimulus); no EFs are taxed. On Block 2 (the incongruent block), participants had to resist that prepotent response and instead press on the side opposite the stimulus. On Block 3 (the mixed block), the two types of trials are randomly intermixed, requiring remembering both rules and mentally translating “same [or opposite] side” into “right [or left] hand,” and flexibly switching between the two rules, inhibiting one to apply the other.

The children came to the study center mid-morning and first performed a warm up task (about 5 min). During the task, children were told to respond to a stimulus as fast as they were able and this gave them practice with the computerized set-up. The children then performed the H&F task (about 10 min). Practice trials were given before both the congruent and incongruent blocks (see Davidson et al., 2006; Diamond et al., 2007). In both blocks, children were given up to 6 s to respond, and 10 s in the mixed block. Responses > 2000 ms were considered incorrect (inattentive) and those < 250 ms, impulsive. Both responses were excluded. Five trials out of 1860 trials were > 2000 ms (0.26%), and there were no trials < 250 ms (out of 1860 trials in total). Outlier trials were removed by using a lower and upper threshold of 2 standard deviations from the mean RT per trial type per block and per subject.

Two dependent measures were tabulated for each block (i.e., Congruent, Incongruent, etc): (1) correct responses or accuracy (% correct = #correct/[# trials]) and (2) Reaction time or speed of response (reaction time, RT > 250 msec for correct trials only). Reaction time was a Choice RT tabulated every time a stimulus appeared during the three-block task and the stimulus appeared at random intervals (one button used) (Kail and Salthouse, 1994).

Maternal mood

Maternal mood was assessed during the third trimester of pregnancy (mean 33.8 week; SD 1.25 weeks), and again at the 6-year timepoint using the HAM-D; (Hamilton, 1960), a 21-item clinician-rated measure of depressive symptoms with a score ranging from 0 to 63.

SLC6A4 genotyping

Genomic DNA was extracted from neonatal whole blood samples using the Flexigene DNA Blood Kit (Qiagen, Valencia, California). The S and L alleles of SLC6A4 were identified as previously described in (Lesch et al., 1993). Polymerase chain reaction was performed with oligonucleotide primers flanking the polymorphism (corresponding to nucleotide positions -1416 to -1397 [stpr5, 5_- GGCGTTGCCGCTCTGAATGC] and -910 to -888 [stpr3, 5_-GAGGGACTGAGCTGGACAACCAC]) of the 5_-flanking regulatory region of SLC6A4 to generate a 484-bp (S short allele) or a 528-bp (L long allele) polymerase chain reaction product. Polymerase chain reaction amplification was performed in a final volume of 30 μ L with 50 ng of genomic DNA, 2.5mM deoxyribonucleotides (dGTP/7-deaza-2_-dGTP = l/l), 0.1 μ g of sense and antisense primers, 10 mM Tris hydrochloride (pH 8.3), 50 mM potassium chloride, 1.5 mM magnesium chloride, and 1 U of Taq DNA polymerase. For quality control, 5% of the samples were randomly chosen to be retested and their genotypes were consistent with previous results.

Statistical analyses

Two separate analytic approaches were used to study behavioral outcomes. To analyze child behavioral differences using maternal report, a multivariate analysis of covariance (MANCOVA) was used to examine group (SRI exposed vs. non exposed) differences in child behavior, with child age (at the time of the 6 year study, prenatal (3rd trimester) and postnatal (6 year) maternal mood as covariates. Maternal mood was used as a continuous measure to allow us to account for the wide range of depressive symptoms observed among both SRI-exposed and non-exposed groups. Across time, some mothers in our untreated group became depressed and some crossed over to the SRI treated group. Maternal mood measures at both time points (prenatally and at the 6 year study) helped to account for these changes.

General Estimating Equation (GEE) modeling was used to examine group (SRI exposed vs. non-exposed) and genotype (LL vs. at least one S allele) in relation to each of the three computerized H&F conditions. Due to a limited number of children with SRI exposure and two short alleles (n = 7), children with at least one short allele (LS and SS) were grouped together to yield the ≥1 S allele group. With the GEE approach we were able to examine main effects (SRI exposure and genotype) and interactions simultaneously. The role of genotype was examined as a possible moderator of the effects of prenatal exposure on EFs by comparing performance for each EF task block and interactions between exposure group and SLC6A4 genotype (LL vs. at least one S allele [SS or LS]), accounting for pre- and post-natal maternal mood. GEE extends the generalized linear modeling to allow for analysis of repeated measurement of accuracy (a binomial dependent variable). GEE analyses were performed using SPSS Statistics 18. All p-values less than 0.05 were considered significant.

Results

Demographic and behavioral outcomes for the mothers and their children are presented in Tables 1, 2. With the exception of maternal education, maternal mood prenatally and at the 6 year study, child age at the time of the study (p = 0.03), and the children's 5-min APGAR scores (p = 0.026), no significant group differences (SRI exposed vs. non-exposed) were observed. As SRI-exposed children were older than the non-exposed children at the time of the study, child age was included as a covariate in the analyses. While the 5-min APGAR scores were statistically different between groups, the clinical impact of these differences (i.e., between scores of 9.13 vs. 8.73, Table 1) would not reflect a significant difference in outcome and thus were not included in further analyses. We did not include maternal education as a covariate as all mothers had high levels of education.

Table 2.

Child characteristics.

Child characteristics Non-exposed (n = 38) SRI-exposed (n = 26) T p-value
Gestation age at birth (mean weeks) (SD) 40.0 (1.35) 39.4 (1.63) 1.54 0.128
Birth weight (grams) (SD) 3531 (470) 3317 (480) 1.77 0.081
Birth length (cm) (SD) 51.7 (2.8) 50.71 (2.54) 1.48 0.143
Head circumference (cm) (SD) 35.0 (1.36) 34.42 (1.27) 1.69 0.095
Apgars score (1 min) 8.03 (1.6) 7.65 (1.55) 0.93 0.358
Apgars score (5 min) 9.13 (0.53) 8.73 (0.87) 2.28 0.026
Sex (m:f) 18:20 10:16 −0.7 0.488
SLC6A4 genotype (n's) 0.946
LL 11 9
1S 23 16
Age at study (yr) (SD) 6.22 (0.55) 6.51 (0.45) −2.28 0.03
Child mental health symptomatology F p-value
Internalizing symptoms^ Composite of depression, separation anxiety, and generalized anxiety scores 0.33 (0.25) 0.33 (0.22) 0.253 0.617
% above clinical threshold 6.3 8
Externalizing symptoms^ Composite of oppositional defiant behaviors and conduct problem scores 0.29 (0.22) 0.23 (0.17) 5.831 0.019
% above clinical threshold 6.3 0
ADHD Symptoms^ Composite of inattention, impulsivity, and hyperactivity scores 0.67 (0.39) 0.47(0.37) 4.954 0.03
% above clinical threshold 9.4 0
^

Controlling for maternal mood (prenatal and 6 year) and child age.

Child mental health

In SRI-exposed children, significantly fewer ADHD (p = 0.03) and disruptive externalizing symptoms (p = 0.019) were reported by parents, after adjusting for child age, 3rd-trimester maternal mood and maternal mood at the time of the study. No differences in internalizing behaviors were found between exposure groups (Table 2). Maternal depression symptoms were associated with increased report of externalizing (r = 0.314; p = 0.01) and ADHD behaviors (r = 0.251; p = 0.039). In separate GEE models, internalizing and externalizing behaviors, respectively, were not predictive of EF performance, regardless of concurrent mother's mood.

EF task (hearts and flowers)

To examine the effect of SRI exposure, SLC6A4 variant and maternal mood on EF performance (accuracy and reaction time), a GEE model was run separately on each of the three blocks of the EF task. SRI exposure (yes/no) and SLC6A4 variant (LL vs. at least one S) were factors. Trials was a repeated within-subject variable, and maternal mood measures (prenatal and at the 6 year study) and child age at test day were covariates. The outcome was either accuracy (% correct response) or RT (in milliseconds) on the EF task.

Reaction time

Overall, no SRI exposure group differences in RT (Figure 1) were found in any of the 3 blocks. RT increased with increasing task difficulty, but that did not differ by SRI exposure or genotype (LL vs. ≥1 S allele). In a separate analysis of Choice RT task, older children were faster (B = −35.5, p = 0.048). To control for speed of responding faster, Choice RT was added to an overall GEE RT model as a covariate. There was still no significant effect for SRI exposure or SLC6A4 genotype (LL vs. ≥1 S allele) in the GEE RT model.

Figure 1.

Figure 1

Reaction Time (ms ± sem) by block and SRI Exposure.

Accuracy

Overall, no SRI exposure group differences in accuracy (Figure 2) were found on block 1 or 2. Differences emerged in the most difficult third block where exposed children showed higher accuracy (suggesting better cognitive flexibility). However, the results were not significant when controlling for child age. Not surprisingly, older children performed better on the EF test (p = 0.004); the results of the models were adjusted for child age. Maternal depressed mood at 3rd trimester contributed, but not statistically significantly (p = 0.064, OR = 0.943).

Figure 2.

Figure 2

Accuracy (CR % ± SEM) by block and SRI exposure (CR% corrected for age).

With each block, differences in accuracy between allelic variations and exposure groups began to emerge, but only in block 3, with accuracy as the dependent variable, a significant main effect for SLC6A4 genotype, child age and maternal mood emerged, as well as a significant 3-way interaction between prenatal SRI exposure, SLC6A4 variant, and maternal mood at age 6 years in the GEE model (Table 3), controlling for child age.

Table 3.

GEE model results (reflecting slope) showing the effect of SRI exposure, SLC6A4 variant, and maternal mood on EF task accuracy.

Parameter B* 95% Wald confidence interval Wald χ 2 p-value
Lower Upper
SRI exposure 0.516 −0.236 1.268 1.807 0.179
SLC6A4 LL 1.051 0.263 1.838 6.838 0.009
Third trimester mood (HAMD) −0.059 −0.122 0.003 3.429 0.064
Maternal Mood Study Day (HAMD) 0.099 0.035 0.163 9.295 0.002
Child age at study day 0.682 0.221 1.143 8.398 0.004
Prenatal mood * SRI non-exposed * SLC6A4 LL −0.047 −0.162 0.068 0.632 0.427
Prenatal mood * SRI non-exposed * SLC6A4 ≥ 1 s 0.056 −0.024 0.136 1.884 0.17
Prenatal Mood * SRI exposed * SLC6A4 LL −0.02 −0.094 0.055 0.271 0.602
Six year maternal mood * SRI non-exposed * SLC6A4 LL −0.171 −0.261 −0.082 14.098 <0.001
Six year maternal mood * SRI non-exposed * SLC6A4 ≥ 1 s −0.139 −0.216 −0.061 12.237 <0.001
Six year maternal mood * SRI exposed * SLC6A4 LL −0.092 −0.171 −0.014 5.29 0.021

B

*

is the non-standardized regression coefficient. Bold value indicates p < 0.001.

When the mother's current depressed mood symptoms were relatively low (measured on test-day), EF performance did not differ with the presence of prenatal SRI exposure (Figure 2) or by child genotype (Figure 3A, using maternal mood grouped by quartiles to illustrate the GEE results). However, the more depressed the mother was currently, the more performance between the groups began to diverge. In the face of higher depressive maternal symptoms (4th quartile), EF performance of children with no prenatal SRI exposure was poor. Accuracy was significantly and inversely related to how depressed their mother was currently (B = 0.099; 95% CI [0.035–0.163]; χ2 = 9.295; p = 0.002) and this was particularly true for children with the LL variant (B = −0.092; 95% CI [−0.171–−0.014]; χ2 = 5.29; p = 0.021). Namely, children prenatally exposed to SRIs and with at least 1 S allele and high concurrent maternal depressive symptoms showed no decrement in accuracy. However, among children with LL variant of SLC6A4, accuracy was worse in children with symptomatic mothers (3rd and 4th quartiles) compared with those with less symptomatic mothers. In contrast, children with = 1 S allele had relatively stable performance regardless of mothers' depressive mood states (Figure 3B).

Figure 3.

Figure 3

(A) Accuracy (% Correct Response, Block 3 ± SEM), SRI exposure & Maternal Depressed Mood at 6 years postpartum (quartile). Trend lines reflect differences in CR% across maternal mood between exposure groups. (B) Accuracy (CR%, Correct Response, Block 3 ± SEM), SLC6A4 Allelic variations & Maternal Depressed Mood at 6 years postpartum (quartile). Trend lines reflect differences in CR% across maternal mood between allele groups.

Discussion

On a test of EFs (H&F; requiring inhibition, working memory, and cognitive flexibility), the effect of prenatal SRI exposure was markedly different in 6-year-old children depending on the child's SLC6A4 genotype and mother's concurrent mood. SRI exposed children with an LL genotype showed pronounced differences in their EFs depending on their mother's current mood. SRI-exposed children with at least one short SLC6A4 allele showed resilience (no impairment in inhibition and attention). Even in the face of more symptomatic mothers, the accuracy of the ≥1 S children on the difficult mixed Block 3 of the H&F test did not differ. In contrast, children with two L alleles, were far more sensitive to the context of life with a depressed mother. When their mother had few or no depression symptoms, LL children did extremely well—no other group regardless of SLC6A4 genotype or mother's mood had mean scores that were as high. However, when their mothers were highly symptomatic, they performed worse than any other group including ≥1 S children with equally symptomatic mothers and LL children with less symptomatic mothers.

Differences in accuracy were most evident on the most-demanding EF Block. In general EF differences between groups often emerge only when cognitive skills are pushed to their limit. Children's EFs were not significantly affected by the child's mood (anxiety or depressive symptoms), though in this cohort there was little variation in the children's subclinical mood symptoms. Parents reported fewer inattentive and externalizing behaviors in children with prenatal SRI exposure regardless of the child's genotype. That might be because the SRI improved the child's postnatal environment (by improving the mother's mood) or because the effect on the 5HT signaling in the child secondary to prenatal SRI exposure. The benefit of one S allele of SLC6A4 to EFs (cognitive control, self-regulation, inhibitory control) in children prenatally exposed to an SRI antidepressant became most apparent when children were in a particular environment (i.e., when their mothers were relatively more depressed). In that environment, the effects of the LL exposed children suffered but the effects of the exposed with ≥1 S allele did not. In this way maternal depression might act as a “prism,” dramatically increasing variability in EFs, according to prenatal SRI exposure and allelic variation.

Critical to identifying the impact of prenatal SRI exposure, is distinguishing the effects of the antidepressant from the maternal mood disturbance (pre and postnatal) that resulted in antidepressant medication use. Sensitivity to maternal depressed mood and its impact on cognitive development has been widely reported across childhood (Gelfand and Teti, 1990; Goodman and Gotlib, 1999; Elgar et al., 2004; Gross et al., 2008). Long before birth, early life influences are already shaping core cognitive capacities that go on to become critical for learning and mental health during childhood (Kolb et al., 2003; Fox et al., 2010). Preterm birth (Davis et al., 2011), prenatal psychological distress (Buss et al., 2011) and maternal behavioral risks (smoking, alcohol use, drug use) (Espy et al., 1999; Schonfeld et al., 2006; Blood-Siegfried and Rende, 2010) exert an influence on early EFs. Early and chronic exposure to maternal symptoms adversely affects early development of EFs (Hughes et al., 2013). Yet, not all outcomes on cognitive developmental pathways are necessarily negative in this setting (DiPietro et al., 2006), raising critical questions of how maternal mood affects cognitive development and who remains at risk, even in the presence of maternal pharmacotherapy. In the present study, prenatal SRI exposed children with at least one S allele showed stable EF functioning regardless of whether their mother was more or less depressed. Moreover, maternal mood in the present study, when their children were 6 years old, was mainly at a subthreshold level, well-below a typical DSM-IV criteria for Major Depressive Diorder (MDD; American Psychiatric Association, 2000), thus highlighting the importance of a spectrum of maternal mood symptoms on child development, rather than a clinical cutoff score.

Converging evidence also points to links between changes in 5-HT signaling and cognition in both animal models and humans (Munafò et al., 2009; Homberg et al., 2010), though not all studies have been consistent (Schmitt et al., 2006; Homberg and Lesch, 2011). Increased 5-HT signaling, secondary to SRI treatment and genetic variations, has been associated with improved cognitive functions. 5-HT transporter knockout rodent models, analogous to an extremely low activity (short allele) variant, have been associated with improved cognitive flexibility during reversal learning tasks (Brigman et al., 2010; Nonkes et al., 2012), as well as morphological frontal cortex changes reflecting an increase in central 5-HT levels (Jedema et al., 2009; Kalueff et al., 2010; Nonkes et al., 2010). Consistent with these findings, early developmental exposure to fluoxetine has been associated with improved spatial learning in rats (Bairy et al., 2006). In humans, carriers of the S allele showed improved performance on an attentional inhibition task (Roiser et al., 2007). Adults homozygous for SS alleles outperform LL carriers on cognitive tasks requiring inhibitory control, including episodic memory and attention (Roiser, 2011), reaction time (Enge et al., 2011) and executive attention (Strobel et al., 2007). Among S carriers, better performance on the Wisconsin Card Sorting test has been reported (Borg et al., 2009), reflecting the impact of increased 5-HT signaling on cognitive flexibility. In contrast, lower 5-HT levels also appear to impair reversal learning (Clarke et al., 2007). Cognitive consequences of increased 5-HT signaling associated with SRI antidepressant exposure have shown mixed results as well. In animal models, not all findings reflect the same impact on cognitive flexibility (Homberg et al., 2007b).

The neuroanatomical, and functional consequences of changing 5-HT levels depend on the timing (critical periods) and direction (increased or decreased) of the developmental exposure to changes in 5-HT signaling and may differ from the impact of an acute exposure in a mature organism. (Ansorge et al., 2007; Kalueff et al., 2010). In a rodent model, SRI exposure during a very specific postnatal period (postnatal days 4–21) of development is also associated, paradoxically, with reduced exploratory behavior, and depressive and anxiety-related behaviors in adulthood. These effects mimic the very effects of genetic 5-HTT inactivation (i.e., gene knockout models leading to the absence of the transporter); suggesting that increased serotonergic signaling during a developmentally critical period predisposes to subsequent affective disturbances (Lira et al., 2003; Ansorge et al., 2004, 2008). This central serotonergic auto-feedback hypothesis suggests that increased feedback signaling in the presence of high serotonergic tone blunts maturation of the 5-HT system via long-term developmental activation of inhibitory receptors (i.e., 5-HT1a), paradoxically leading to psychopathology later in life (Hensler, 2006; Ansorge et al., 2007; Simpson et al., 2011). While one might consider that maternal SRI treatment during pregnancy could potentially confer benefit on fetal neurodevelopment—via improved maternal mood—such exposure could also have detrimental effects later in childhood, reflecting a long-term consequence of decreased serotonergic tone. SRIs may elevate fetal 5-HT levels, but then ultimately lead to decreased 5-HT signaling later in life and restricted serotonergic system development. The serotonergic auto-feedback hypothesis, however, is not a unitary construct and further work is needed to understand how developmental changes in 5-HT signaling influences the downstream interaction with the social environment inherent to life with a depressed mother that together contributes to childhood behavior in this setting (Oberlander et al., 2009).

Importantly, not all factors that affect 5-HT signaling confer the same risk. Early life experiential variables influence susceptibility to environmental factors (Moffitt et al., 2005; Caspi and Moffitt, 2006) and not all outcomes associated with the short allele are necessarily negative (Risch et al., 2009). While adults with two short alleles may be at increased risk for depression (Caspi et al., 2003) following early life adversity, those raised in a nurturing environment may ultimately have a lower risk for depressive symptoms (Taylor et al., 2006). Increased central 5-HT associated with the SLC6A4 short allele may therefore contribute to an increased sensitivity to environmental stimuli or hyper vigilance, leading to adaptation in one setting or an increased risk for poor mental health in another. In other words, in a low reward or low adversity setting, such hyper vigilance may confer an actual benefit that increases processing of relevant stimuli improving learning and social cognition (Homberg and Lesch, 2011). In the current study, serotonergic tone, via either prenatal SRI exposure or SLC6A4 allelic variations, appeared to affect a self-regulatory capacity that might heighten sensitivity to a world with a depressed mother. Highly vigilant individuals may therefore either become vulnerable or resilient, depending on the demands of that social environment.

Our findings may also illustrate the influence of how allelic variations in the context of both early (i.e., fetal) and ongoing (i.e., postnatal/childhood) life experience shape a “biological sensitivity to context” (Boyce et al., 1995; Ellis et al., 2011) influencing adaptation and the diversity of child developmental outcomes following early changes in 5-HT signaling. This model proposes that phenotypic plasticity might enable a child to match their biological and behavioral capacities to the demands of their developmental environment. In this context, genetic variations may confer advantages for some children in supportive environments, but disadvantages for others who face social adversity in the context of maternal depression (Boyce and Ellis, 2005). Our findings showing higher accuracy in the non-exposed, LL children in the context of a minimally depressed mother, supports this claim.

Our findings point to a broader understanding of the impact of serotonin developmental neurobiology. While the “S” allele has been widely considered the “risk” or “sensitive” allele whereby the effect varies with context (Barr et al., 2004; Belsky and Pluess, 2009; Homberg and Lesch, 2011; van Ijzendoorn et al., 2012) our findings suggest that under certain circumstances carriers of the L allele may also be equally or even more sensitive to context. How this reflects the underlying changes in serotonin signaling (i.e., increased or decreased serotonin at developmentally sensitive times) remains a matter of speculation (Oberlander et al., 2009). Under some circumstances the L allele may confer vulnerability such as fear in adults exposed to carbon dioxide (Schruers et al., 2011) or aggression in 3-year old children of prenatally anxious mothers (Oberlander et al., 2010) when compared with LS or S allele carriers. Our findings take this observation one step further. Even with similar prenatal exposures, two children with different genetic inheritance show divergent developmental outcomes depending on the environmental circumstances they find themselves in at 6 years of age. Namely, while the impact of allelic variations may be environmentally dependent and the influence can, depending on the childhood context they grow into, go in both directions, thereby reflecting both developmental risk in some settings and resiliency in others. In this way, gene by environment outcomes may reflect a “conditional adaptation” (Boyce and Ellis, 2005) whereby allelic variations can be susceptible to both stressful and supportive contexts—for better and for worse (Belsky et al., 2007).

Conceivably there could be both advantages and disadvantages to improved EF performance. On one hand heightened vigilance may reflect an increased sensitivity in the social world of early childhood. However, it may also reflect a relative deficit in self-regulatory capacity which might illustrate a “leading edge” or susceptibility for a mood disorder that may emerge later in childhood (Taghavi et al., 1999). Interestingly, in a rodent model, an early increase in 5-HT signaling was associated with early fluoxetine exposure and paradoxically leads to increased anxiety and depression behaviors in adulthood (Ansorge et al., 2004). Earlier we reported that increased anxiety and depressive symptoms were observed by parents in 3 year olds with prenatal SRI exposure, though current increased maternal depression symptoms also contributed to child behavior (Oberlander et al., 2010). Now by 6 years of age, in the same cohort, levels of anxious behaviors did not differ between non-exposed children and fewer externalizing and attentional behaviors were observed in the exposed children. The long term implications of this unfolding longitudinal pattern remains unknown, however, improved EFs may reflect an endophenotype that includes increased vigilance that may evolve into a clinically apparent mood disorder in later childhood. Although increased vigilance may confer benefits for short-term tasks in one context (e.g., during a laboratory EF testing), it may be disadvantageous in the long run under other typical childhood circumstances (e.g., during an entire school day). While improved cognitive control in one setting may confer a developmental advantage (such as life with a depressed mother), the long term consequences of our findings in other childhood contexts (e.g., stressful classroom) need further study.

Limitations

A number of limitations need mentioning. First, without direct measures of central changes in 5-HT signaling in utero and again at 6 years, we can only infer that prenatal SRI exposure and genetic variations did indeed alter 5-HT function accounting for our findings. Further, serotonergic system function is dependent on multiple neurochemicals, receptors and related genes, and a focus on prenatal SRI exposure and genetic variations for 5-HT transporters offer only a limited insight into a complex developmental system underlying early human cognitive development. Additionally, study of parent-child relationships which have been noted as key influences on individual differences in a developing child's executive capacities (Carlson, 2003; Hughes and Ensor, 2009; Bernier et al., 2011) are needed.

Summary

This study sought to examine the long-term effects of prenatal SRI exposure on EFs at 6 years of age and to determine whether effects are moderated by maternal mood and/or genetic variations. For prenatally SRI-exposed children, regardless of maternal mood, accuracy of children with reduced 5HTT expression (at least one short [S] allele) remained stable regardless of maternal depressive symptoms. In particular, even with somewhat depressed mothers (though all symptoms were below clinical threshold), these children's EFs were comparable to children with the same genotype whose mothers showed few if any depressive symptoms—in this sense, they showed resilience. In contrast, children with two long (L) alleles appeared sensitive to context. When their mothers reported relatively fewer depressed symptoms, LL children showed extremely good EF performance—better than any other group. When mothers reported more depressive symptoms, LL children's EF performance was worse than that of any other group. Further, parents reported fewer inattentive behaviors in their SRI exposed children.

In the face of a mother with a relatively more depressed mood (albeit not at clinical levels), EFs were best preserved in children prenatally exposed to SRIs and with at least one short SLC6A4 allele. Yet, prenatally-exposed LL children hold out promise of possibly superior EF if their mother's mood remains euthymic or improves. Together these findings may reflect effects of both increased and decreased early serotonergic signaling associated with an increased sensitivity to social and relational contexts. While improved EFs might reflect an apparent resiliency to an “at risk” social environment, the long term and clinical implications of these findings remain to be determined.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

We thank the mothers and their children who participated and contributed to this work. We are grateful to Joannie Maynard and Deborah Heard for their assistance with data collection. This research was funded by March of Dimes Foundation (USA), the Child and Family Research Institute (UBC) and the Canadian Institutes of Health Research [Tim F. Oberlander (PI), CIHR #MOP 57837] and 6 year grant (MOP-86296). Tim F. Oberlander is the R. Howard Webster Professor in Brain Imaging and Early Child Development (UBC). Whitney M. Weikum was supported by postdoctoral fellowships from CIHR, Michael Smith Foundation for Health Research and funding from the Sunny Hill Foundation. Funding sources had no role in the study.

References

  1. Ablow J. C., Measelle J. R., Kraemer H. C., Harrington R., Luby J., Smider N., et al. (1999). The macarthur three-city outcome study: evaluating multi-informant measures of young children's symptomatology. J. Am. Acad. Child Adolesc. Psychiatry 38, 1580–1590 10.1097/00004583-199912000-00020 [DOI] [PubMed] [Google Scholar]
  2. American Psychiatric Association. (2000). Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR®. Washington, DC: American Psychiatric Pub [Google Scholar]
  3. Ansorge M. S., Hen R., Gingrich J. A. (2007). Neurodevelopmental origins of depressive disorders. Curr. Opin. Pharmacol. 7, 8–17 10.1016/j.coph.2006.11.006 [DOI] [PubMed] [Google Scholar]
  4. Ansorge M. S., Morelli E., Gingrich J. A. (2008). Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. J. Neurosci. 28, 199–207 10.1523/JNEUROSCI.3973-07.2008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Ansorge M. S., Zhou M., Lira A., Hen R., Gingrich J. A. (2004). Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306, 879–881 10.1126/science.1101678 [DOI] [PubMed] [Google Scholar]
  6. Bairy K., Madhyastha S., Ashok K., Bairy I., Malini S. (2006). Developmental and behavioral consequences of prenatal fluoxetine. Pharmacology 79, 1–11 10.1159/000096645 [DOI] [PubMed] [Google Scholar]
  7. Barr C. S., Newman T. K., Lindell S., et al. (2004). Interaction between serotonin transporter gene variation and rearingcondition in alcohol preference and consumption in female primates. Arch. Gen. Psychiatry 61, 1146–1152 10.1001/archpsyc.61.11.1146 [DOI] [PubMed] [Google Scholar]
  8. Belsky J., Bakermans-Kranenburg M. J., van IJzendoorn M. H. F. (2007). For better and for worse: differential susceptibility to environmental influences. Curr. Dir. Psychol. Sci. 16, 300–304 10.1111/j.1467-8721.2007.00525.x [DOI] [Google Scholar]
  9. Belsky J., Pluess M. (2009). Beyond diathesis stress: differential susceptibility to environmental influences. Psychol. Bull. 135, 885–908 10.1037/a0017376 [DOI] [PubMed] [Google Scholar]
  10. Bernier A., Carlson S. M., Deschênes M., Matte-Gagné C. (2011). Social factors in the development of early executive functioning: a closer look at the caregiving environment. Dev. Sci. 15, 12–24 10.1111/j.1467-7687.2011.01093.x [DOI] [PubMed] [Google Scholar]
  11. Blair C. (2002). School readiness: Integrating cognition and emotion in a neurobiological conceptualization of children's functioning at school entry. Am. Psychol. 57, 111 10.1037/0003-066X.57.2.111 [DOI] [PubMed] [Google Scholar]
  12. Blair C., Granger D., Peters Razza R. (2005). Cortisol reactivity is positively related to executive function in preschool children attending Head Start. Child Dev. 76, 554–567 10.1111/j.1467-8624.2005.00863.x [DOI] [PubMed] [Google Scholar]
  13. Blair C., Razza R. P. (2007). Relating effortful control, executive function, and false belief understanding to emerging math and literacy ability in kindergarten. Child Dev. 78, 647–663 10.1111/j.1467-8624.2007.01019.x [DOI] [PubMed] [Google Scholar]
  14. Blood-Siegfried J., Rende E. K. (2010). The long-term effects of prenatal nicotine exposure on neurologic development. J. Midwifery Womens Health 55, 143–152 10.1016/j.jmwh.2009.05.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Borg J., Henningsson S., Saijo T., Inoue M., Bah J., Westberg L., et al. (2009). Serotonin transporter genotype is associated with cognitive performance but not regional 5-HT1A receptor binding in humans. Int. J. Neuropsychopharmacol. 12, 783–792 10.1017/S1461145708009759 [DOI] [PubMed] [Google Scholar]
  16. Boyce W. T., Chesney M., Alkon A., Tschann J. M., Adams S., Chesterman B., et al. (1995). Psychobiologic reactivity to stress and childhood respiratory illnesses: results of two prospective studies. Psychosom. Med. 57, 411–422 [DOI] [PubMed] [Google Scholar]
  17. Boyce W. T., Ellis B. J. (2005). Biological sensitivity to context: I. An evolutionary-developmental theory of the origins and functions of stress reactivity. Dev. Psychopathol. 17, 271–301 10.1017/S0954579405050145 [DOI] [PubMed] [Google Scholar]
  18. Boyce W. T., Essex M. J., Woodward H. R., Measelle J. R., Ablow J. C., Kupfer D. J. (2002). The confluence of mental, physical, social, and academic difficulties in middle childhood. I: exploring the “headwaters” of early life morbidities. J. Am. Acad. Child Adolesc. Psychiatry 41, 580–587 10.1097/00004583-200205000-00016 [DOI] [PubMed] [Google Scholar]
  19. Boyle M. H., Offord D. R., Racine Y., Fleming J. E., Szatmari P., Sanford M. (1993). Evaluation of the revised Ontario child health study scales. J. Child Psychol. Psychiatry 34, 189–213 10.1111/j.1469-7610.1993.tb00979.x [DOI] [PubMed] [Google Scholar]
  20. Braver T. S., Cohen J. D., Barch D. M. (2002). The role of the prefrontal cortex in normal and disordered cognitive control: a cognitive neuroscience perspective, in Principles of Frontal Lobe Function, eds Stuss D. T., Knight R. T. (Oxford, England: Oxford University Press; ), 428–448 [Google Scholar]
  21. Brigman J. L., Mathur P., Harvey-White J., Izquierdo A., Saksida L. M., Bussey T. J., et al. (2010). Pharmacological or genetic inactivation of the serotonin transporter improves reversal learning in mice. Cereb. Cortex 20, 1955–1963 10.1093/cercor/bhp266 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Bull R., Scerif G. (2001). Executive functioning as a predictor of children's mathematics ability: Inhibition, switching, and working memory. Dev. Neuropsychol. 19, 273–293 10.1207/S15326942DN1903_3 [DOI] [PubMed] [Google Scholar]
  23. Buss C., Davis E., Hobel C., Sandman C. (2011). Maternal pregnancy-specific anxiety is associated with child executive function at 6-9 years age. Stress 14, 665–676 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Canli T., Omura K., Haas B. W., Fallgatter A., Constable R. T., Lesch K. P. (2005). Beyond affect: a role for genetic variation of the serotonin transporter in neural activation during a cognitive attention task. Proc. Natl. Acad. Sci. U.S.A. 102, 12224–12229 10.1073/pnas.0503880102 [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Carlson S. M. (2003). Executive function in context: development, measurement, theory, and experience. Monogr. Soc. Res. Child Dev. 68, 138–151 10.1111/j.1540-5834.2003.06803012.x [DOI] [PubMed] [Google Scholar]
  26. Caspi A., Moffitt T. E. (2006). Gene–environment interactions in psychiatry: joining forces with neuroscience. Nat. Rev. Neurosci. 7, 583–590 10.1038/nrn1925 [DOI] [PubMed] [Google Scholar]
  27. Caspi A., Sugden K., Moffitt T. E., Taylor A., Craig I. W., Harrington H., et al. (2003). Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301, 386–389 10.1126/science.1083968 [DOI] [PubMed] [Google Scholar]
  28. Champod A. S., Petrides M. (2007). Dissociable roles of the posterior parietal and the prefrontal cortex in manipulation and monitoring processes. Proc. Natl. Acad. Sci. U.S.A. 104, 14837–14842 10.1073/pnas.0607101104 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Clarke H., Walker S., Dalley J., Robbins T., Roberts A. (2007). Cognitive inflexibility after prefrontal serotonin depletion is behaviorally and neurochemically specific. Cereb. Cortex 17, 18–27 10.1093/cercor/bhj120 [DOI] [PubMed] [Google Scholar]
  30. Cooper W. O., Willy M. E., Pont S. J., Ray W. A. (2007). Increasing use of antidepressants in pregnancy. Am. J. Obstet. Gynecol. 196, 544e1–544.e5. 10.1016/j.ajog.2007.01.033 [DOI] [PubMed] [Google Scholar]
  31. Davidson M. C., Amso D., Anderson L. C., Diamond A. (2006). Development of cognitive control and executive functions from 4 to 13 years: evidence from manipulations of memory, inhibition, and task switching. Neuropsychologia 44, 2037 10.1016/j.neuropsychologia.2006.02.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Davis E. P., Buss C., Muftuler L. T., Head K., Hasso A., Wing D. A., et al. (2011). Children's brain development benefits from longer gestation. Front. Psychol. 2, 1–7 10.3389/fpsyg.2011.00001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Diamond A. (2011). Biological and social influences on cognitive control processes dependent on prefrontal cortex. Prog. Brain Res. 189, 319–339 10.1016/B978-0-444-53884-0.00032-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Diamond A. (2013). Executive Functions. Annu. Rev. Psychol. 64, 135–168 10.1146/annurev-psych-113011-143750 [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Diamond A., Barnett W. S., Thomas J., Munro S. (2007). Preschool program improves cognitive control. Science 318, 1387–1388 10.1126/science.1151148 [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. DiPietro J. A., Novak M. F. S. X., Costigan K. A., Atella L. D., Reusing S. P. (2006). Maternal psychological distress during pregnancy in relation to child development at age two. Child Dev. 77, 573–587 10.1111/j.1467-8624.2006.00891.x [DOI] [PubMed] [Google Scholar]
  37. Elgar F. J., McGrath P. J., Waschbusch D. A., Stewart S. H., Curtis L. J. (2004). Mutual influences on maternal depression and child adjustment problems. Clin. Psychol. Rev. 24, 441–459 10.1016/j.cpr.2004.02.002 [DOI] [PubMed] [Google Scholar]
  38. Ellis B. J., Boyce W. T., Belsky J., Bakermans-Kranenburg M. J. (2011). Differential susceptibility to the environment: an evolutionary-neurodevelopmental theory. Dev. Psychopathol. 23, 7 10.1017/S0954579410000611 [DOI] [PubMed] [Google Scholar]
  39. Enge S., Fleischhauer M., Lesch K. P., Reif A., Strobel A. (2011). Serotonergic modulation in executive functioning: linking genetic variations to working memory performance. Neuropsychologia 49, 3776–3785 10.1016/j.neuropsychologia.2011.09.038 [DOI] [PubMed] [Google Scholar]
  40. Espy K. A., Kaufmann P. M., Glisky M. L. (1999). Neuropsychologic function in toddlers exposed to cocaine in utero: a preliminary study. Dev. Neuropsychol. 15, 447–460 10.1080/87565649909540761 [DOI] [Google Scholar]
  41. Essex M. J., Boyce W. T., Goldstein L. H., Armstrong J. M., Kraemer H. C., Kupfer D. J. (2002). The confluence of mental, physical, social, and academic difficulties in middle childhood. II: developing the macarthur health and behavior questionnaire. J. Am. Acad. Child Adolesc. Psychiatry 41, 588–603 10.1097/00004583-200205000-00017 [DOI] [PubMed] [Google Scholar]
  42. Essex M. J., Kraemer H. C., Armstrong J. M., Boyce W. T., Goldsmith H. H., Klein M. H., et al. (2006). Exploring risk factors for the emergence of children's mental health problems. Arch. Gen. Psychiatry 63, 1246–1256 10.1001/archpsyc.63.11.1246 [DOI] [PubMed] [Google Scholar]
  43. Evers E., Van der Veen F., Jolles J., Deutz N., Schmitt J. (2006). Acute tryptophan depletion improves performance and modulates the BOLD response during a Stroop task in healthy females. Neuroimage 32, 248–255 10.1016/j.neuroimage.2006.03.026 [DOI] [PubMed] [Google Scholar]
  44. Fox S. E., Levitt P., Nelson C. A. (2010). How the timing and quality of early experiences influence the development of brain architecture. Child Dev. 81, 28–40 10.1111/j.1467-8624.2009.01380.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Gaspar P., Cases O., Maroteaux L. (2003). The developmental role of serotonin: news from mouse molecular genetics. Nat. Rev. Neurosci. 4, 1002–1012 10.1038/nrn1256 [DOI] [PubMed] [Google Scholar]
  46. Gathercole S. E., Tiffany C., Briscoe J., Thorn A. (2005). Developmental consequences of poor phonological short-term memory function in childhood: a longitudinal study. J. Child Psychol. Psychiatry 46, 598–611 10.1111/j.1469-7610.2004.00379.x [DOI] [PubMed] [Google Scholar]
  47. Gelfand D. M., Teti D. M. (1990). The effects of maternal depression on children. Clin. Psychol. Rev. 10, 329–353 10.1016/0272-7358(90)90065-I [DOI] [Google Scholar]
  48. Gizer I. R., Ficks C., Waldman I. D. (2009). Candidate gene studies of ADHD: a meta-analytic review. Hum. Genet. 126, 51–90 10.1007/s00439-009-0694-x [DOI] [PubMed] [Google Scholar]
  49. Goldman D., Oroszi G., Ducci F. (2005). The genetics of addictions: uncovering the genes. Nat. Rev. Genet. 6, 521–532 10.1038/nrg1635 [DOI] [PubMed] [Google Scholar]
  50. Goodman S. H., Gotlib I. H. (1999). Risk for psychopathology in the children of depressed mothers: a developmental model for understanding mechanisms of transmission. Psychol. Rev. 106, 458 10.1037/0033-295X.106.3.458 [DOI] [PubMed] [Google Scholar]
  51. Gross H. E., Shaw D. S., Moilanen K. L., Dishion T. J., Wilson M. N. (2008). Reciprocal models of child behavior and depressive symptoms in mothers and fathers in a sample of children at risk for early conduct problems. J. Fam. 22, 742 10.1037/a0013514 [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Hamilton M. (1960). A rating scale for depression. J. Neurol. Neurosurg. Psychiatr. 23, 56–62 10.1136/jnnp.23.1.56 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Hanley G. E., Oberlander T. F. (2012). Neurodevelopmental outcomes following prenatal exposure to serotonin reuptake inhibitor antidepressants: a “social teratogen” or moderator of developmental risk? Birth Defects Res. A 94, 651–659 10.1002/bdra.23032 [DOI] [PubMed] [Google Scholar]
  54. Harmer C. J., Bhagwagar Z., Cowen P. J., Goodwin G. M. (2002). Acute administration of citalopram facilitates memory consolidation in healthy volunteers. Psychopharmacology 163, 106–110 10.1007/s00213-002-1151-x [DOI] [PubMed] [Google Scholar]
  55. Heils A., Teufel A., Petri S., Stöber G., Riederer P., Bengel D., et al. (1996). Allelic variation of human serotonin transporter gene expression. J. Neurochem. 66, 2621–2624 10.1046/j.1471-4159.1996.66062621.x [DOI] [PubMed] [Google Scholar]
  56. Hensler J. G. (2006). Serotonergic modulation of the limbic system. Neurosci. Biobehav. Rev. 30, 203–214 10.1016/j.neubiorev.2005.06.007 [DOI] [PubMed] [Google Scholar]
  57. Homberg J. R., Lesch K. P. (2011). Looking on the bright side of serotonin transporter gene variation. Biol. Psychiatry 69, 513–519 10.1016/j.biopsych.2010.09.024 [DOI] [PubMed] [Google Scholar]
  58. Homberg J., Olivier J., Smits B., Mul J., Mudde J., Verheul M., et al. (2007a). Characterization of the serotonin transporter knockout rat: a selective change in the functioning of the serotonergic system. Neuroscience 146, 1662–1676 10.1016/j.neuroscience.2007.03.030 [DOI] [PubMed] [Google Scholar]
  59. Homberg J. R., Pattij T., Janssen M. C., Ronken E., De Boer S. F., Schoffelmeer A. N., et al. (2007b). Serotonin transporter deficiency in rats improves inhibitory control but not behavioural flexibility. Eur. J. Neurosci. 26, 2066–2073 10.1111/j.1460-9568.2007.05839.x [DOI] [PubMed] [Google Scholar]
  60. Homberg J. R., Schubert D., Gaspar P. (2010). New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol. Sci. 31, 60–65 10.1016/j.tips.2009.11.003 [DOI] [PubMed] [Google Scholar]
  61. Hughes C., Roman G., Hart M. J., Ensor R. (2013). Does maternal depression predict young children's executive function?–a 4-year longitudinal study. J. Child Psychol. Psychiatry 54, 169–177 10.1111/jcpp.12014 [DOI] [PubMed] [Google Scholar]
  62. Hughes C. H., Ensor R. A. (2009). How do families help or hinder the emergence of early executive function? New Dir. Child Adolesc. Dev. 2009, 35–50 10.1002/cd.234 [DOI] [PubMed] [Google Scholar]
  63. Jedema H. P., Gianaros P. J., Greer P. J., Kerr D. D., Liu S., Higley J. D., et al. (2009). Cognitive impact of genetic variation of the serotonin transporter in primates is associated with differences in brain morphology rather than serotonin neurotransmission. Mol. Psychiatry 15, 512–522 10.1038/mp.2009.90 [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Kail R., Salthouse T. A. (1994). Processing speed as a mental capacity. Acta Psychol. 86, 199–225 10.1016/0001-6918(94)90003-5 [DOI] [PubMed] [Google Scholar]
  65. Kalueff A., Olivier J., Nonkes L., Homberg J. (2010). Conserved role for the serotonin transporter gene in rat and mouse neurobehavioral endophenotypes. Neurosci. Biobehav. Rev. 34, 373–386 10.1016/j.neubiorev.2009.08.003 [DOI] [PubMed] [Google Scholar]
  66. Kendler K. S., Kuhn J. W., Vittum J., Prescott C. A., Riley B. (2005). The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. Arch. Gen. Psychiatry 62, 529–535 10.1001/archpsyc.62.5.529 [DOI] [PubMed] [Google Scholar]
  67. Kim J., Riggs K. W., Misri S., Kent N., Oberlander T. F., Grunau R. E., et al. (2006). Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. Br. J. Clin. Pharmacol. 61, 155–163 10.1111/j.1365-2125.2005.02538.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. King M. V., Marsden C. A., Fone K. C. (2008). A role for the 5-HT1A, 5-HT 4 and 5-HT6 receptors in learning and memory. Trends Pharmacol. Sci. 29, 482–492 10.1016/j.tips.2008.07.001 [DOI] [PubMed] [Google Scholar]
  69. Kolb B., Gibb R., Robinson T. E. (2003). Brain plasticity and behavior. Curr. Dir. Psychol. 12, 1–5 10.1111/1467-8721.01210 [DOI] [Google Scholar]
  70. Laine K., Heikkinen T., Ekblad U., Kero P. (2003). Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch. Gen. Psychiatry 60, 720–726 10.1001/archpsyc.60.7.720 [DOI] [PubMed] [Google Scholar]
  71. Lee L., Lee L. J. (2012). Neonatal fluoxetine exposure alters motor performances of adolescent rats. Dev. Neurobiol. 72, 1122–1132 10.1002/dneu.20942 [DOI] [PubMed] [Google Scholar]
  72. Lemery-Chalfant K., Schreiber J. E., Schmidt N. L., Van Hulle C. A., Essex M. J., Goldsmith H. (2007). Assessing internalizing, externalizing, and attention problems in young children: validation of the MacArthur HBQ. J. Am. Acad. Child Adolesc. Psychiatry 46, 1315–1323 10.1097/chi.0b013e3180f616c6 [DOI] [PubMed] [Google Scholar]
  73. Lesch K. (2007). Linking emotion to the social brain. EMBO Rep. 8, S24–S29 10.1038/sj.embor.7401008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Lesch K., Bengel D., Heils A., Sabol S. Z., Greenberg B. D., Petri S., et al. (1996). Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274, 1527–1531 10.1126/science.274.5292.1527 [DOI] [PubMed] [Google Scholar]
  75. Lesch K., Wolozin B., Estler H., Murphy D., Riederer P. (1993). Isolation of a cDNA encoding the human brain serotonin transporter. J. Neural Transm. 91, 67–72 10.1007/BF01244919 [DOI] [PubMed] [Google Scholar]
  76. Liao C., Lee L. (2011). Neonatal fluoxetine exposure affects the action potential properties and dendritic development in cortical subplate neurons of rats. Toxicol. Lett. 207, 314–321 10.1016/j.toxlet.2011.09.028 [DOI] [PubMed] [Google Scholar]
  77. Lira A., Zhou M., Castanon N., Ansorge M. S., Gordon J. A., Francis J. H., et al. (2003). Altered depression-related behaviors and functional changes in the dorsal raphe nucleus of serotonin transporter-deficient mice. Biol. Psychiatry 54, 960–971 10.1016/S0006-3223(03)00696-6 [DOI] [PubMed] [Google Scholar]
  78. Luby J. L., Heffelfinger A., Measelle J. R., Ablow J. C., Essex M. J., Dierker L., et al. (2002). Differential performance of the MacArthur HBQ and DISC-IV in identifying DSM-IV internalizing psychopathology in young children. J. Am. Acad. Child Adolesc. Psychiatry 41, 458–466 10.1097/00004583-200204000-00019 [DOI] [PubMed] [Google Scholar]
  79. Mannie Z., Barnes J., Bristow G., Harmer C., Cowen P. (2009). Memory impairment in young women at increased risk of depression: influence of cortisol and 5-HTT genotype. Psychol. Med. 39, 757–762 10.1017/S0033291708004248 [DOI] [PubMed] [Google Scholar]
  80. Miller E. K., Cohen J. D. (2001). An integrative theory of prefrontal cortex function. Annu. Rev. Neurosci. 24, 167–202 10.1146/annurev.neuro.24.1.167 [DOI] [PubMed] [Google Scholar]
  81. Miyake A., Friedman N. P., Emerson M. J., Witzki A. H., Howerter A., Wager T. D. (2000). The unity and diversity of executive functions and their contributions to complex “frontal lobe” tasks: a latent variable analysis. Cognit. Psychol. 41, 49–100 10.1006/cogp.1999.0734 [DOI] [PubMed] [Google Scholar]
  82. Moffitt T. E., Arseneault L., Belsky D., Dickson N., Hancox R. J., Harrington H., et al. (2011). A gradient of childhood self-control predicts health, wealth, and public safety. Proc. Natl. Acad. Sci. U.S.A. 108, 2693–2698 10.1073/pnas.1010076108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Moffitt T. E., Caspi A., Rutter M. (2005). Strategy for investigating interactions between measured genes and measured environments. Arch. Gen. Psychiatry 62, 473–481 10.1001/archpsyc.62.5.473 [DOI] [PubMed] [Google Scholar]
  84. Moses-Kolko E. L., Bogen D., Perel J., Bregar A., Uhl K., Levin B., et al. (2005). Neonatal signs after late in utero exposure to serotonin reuptake inhibitors. J. Am. Med. Assoc. 293, 2372–2383 10.1001/jama.293.19.2372 [DOI] [PubMed] [Google Scholar]
  85. Mulder E. J., Ververs F. F., de Heus R., Visser G. H. (2011). Selective serotonin reuptake inhibitors affect neurobehavioral development in the human fetus. Neuropsychopharmacology 36, 1961–1971 10.1038/npp.2011.67 [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Munafò M. R., Durrant C., Lewis G., Flint J. (2009). Gene× environment interactions at the serotonin transporter locus. Biol. Psychiatry 65, 211–219 10.1016/j.biopsych.2008.06.009 [DOI] [PubMed] [Google Scholar]
  87. Nonkes L. J., Tomson K., Mærtin A. Dederen J. Roald Maes J. Homberg J. (2010). Orbitofrontal cortex and amygdalar over-activity is associated with an inability to use the value of expected outcomes to guide behaviour in serotonin transporter knockout rats. Neurobiol. Learn. Mem. 94, 65–72 10.1016/j.nlm.2010.04.002 [DOI] [PubMed] [Google Scholar]
  88. Nonkes L. J., van de Vondervoort I. I., de Leeuw M. J., Wijlaars L. P., Maes J. H., Homberg J. R. (2012). Serotonin transporter knockout rats show improved strategy set-shifting and reduced latent inhibition. Learn. Mem. 19, 190–193 10.1101/lm.025908.112 [DOI] [PubMed] [Google Scholar]
  89. Nulman I., Rovet J., Stewart D. E., Wolpin J., Pace-Asciak P., Shuhaiber S., et al. (2002). Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am. J. Psychiatry 159, 1889–1895 10.1176/appi.ajp.159.11.1889 [DOI] [PubMed] [Google Scholar]
  90. Oberlander T., Gingrich J., Ansorge M. (2009). Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin. Pharmacol. Ther. 86, 672–677 10.1038/clpt.2009.201 [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Oberlander T. F., Grunau R. E., Fitzgerald C., Ellwood A. L., Misri S., Rurak D., et al. (2002). Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr. Res. 51, 443–453 10.1203/00006450-200204000-00008 [DOI] [PubMed] [Google Scholar]
  92. Oberlander T. F., Grunau R. E., Fitzgerald C., Papsdorf M., Rurak D., Riggs W. (2005). Pain reactivity in 2-month-old infants after prenatal and postnatal selective serotonin reuptake inhibitor medication exposure. Pediatrics 115, 411–425 10.1542/peds.2004-0420 [DOI] [PubMed] [Google Scholar]
  93. Oberlander T. F., Papsdorf M., Brain U. M., Misri S., Ross C., Grunau R. E. (2010). Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3 years of age. Arch. Pediatr. Adolesc. Med. 164, 444–451 10.1001/archpediatrics.2010.51 [DOI] [PubMed] [Google Scholar]
  94. Olivier J., Blom T., Arentsen T., Homberg J. (2011). The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: a review. Prog. Neuro. Psychopharmacol. Biol. Psychiatry 35, 1400–1408 10.1016/j.pnpbp.2010.09.013 [DOI] [PubMed] [Google Scholar]
  95. Owens M., Goodyer I. M., Wilkinson P., Bhardwaj A., Abbott R., Croudace T., et al. (2012). 5-HTTLPR and early childhood adversities moderate cognitive and emotional processing in adolescence. PLoS ONE 7:e48482 10.1371/journal.pone.0048482 [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Petrides M. (2005). Lateral prefrontal cortex: architectonic and functional organization. Philos. Trans. R. Soc. B Biol. Sci. 360, 781–795 10.1098/rstb.2005.1631 [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Popa D., Léna C., Alexandre C., Adrien J. (2008). Lasting syndrome of depression produced by reduction in serotonin uptake during postnatal development: evidence from sleep, stress, and behavior. J. Neurosci. 28, 3546 10.1523/JNEUROSCI.4006-07.2008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Preece M., Dalley J., Theobald D., Robbins T., Reynolds G. (2004). Region specific changes in forebrain 5-hydroxytryptamine 1a and 5-hydroxytryptamine 2a receptors in isolation-reared rats: an in vitro autoradiography study. Neuroscience 123, 725–732 10.1016/j.neuroscience.2003.10.008 [DOI] [PubMed] [Google Scholar]
  99. Reuter M., Ott U., Vaitl D., Hennig J. (2007). Impaired executive control is associated with a variation in the promoter region of the tryptophan hydroxylase 2 gene. J. Cogn. Neurosci. 19, 401–408 10.1162/jocn.2007.19.3.401 [DOI] [PubMed] [Google Scholar]
  100. Riedel W. J., Eikmans K., Heldens A., Schmitt J. A. J. (2005). Specific serotonergic reuptake inhibition impairs vigilance performance acutely and after subchronic treatment. J. Psychopharmacology 19, 12–20 10.1177/0269881105048887 [DOI] [PubMed] [Google Scholar]
  101. Riggs N. R., Blair C. B., Greenberg M. T. (2004). Concurrent and 2-year longitudinal relations between executive function and the behavior of 1st and 2nd grade children. Child Neuropsychol. 9, 267–276 10.1076/chin.9.4.267.23513 [DOI] [PubMed] [Google Scholar]
  102. Risch N., Herrell R., Lehner T., Liang K., Eaves L., Hoh J., et al. (2009). Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression. J. Am. Med. Assoc. 301, 2462–2471 10.1001/jama.2009.878 [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. Roiser J. (2011). Bridging the gap between genes and behaviour: the case for neuroimaging genetics. J. Neurol. Neurosurg. Psychiatry 82, e2 10.1136/jnnp-2011-300504.24 [DOI] [Google Scholar]
  104. Roiser J. P., Blackwell A. D., Cools R., Clark L., Rubinsztein D. C., Robbins T. W., et al. (2006). Serotonin transporter polymorphism mediates vulnerability to loss of incentive motivation following acute tryptophan depletion. Neuropsychopharmacology 31, 2264–2272 10.1038/sj.npp.1301084 [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Roiser J. P., Müller U., Clark L., Sahakian B. J. (2007). The effects of acute tryptophan depletion and serotonin transporter polymorphism on emotional processing in memory and attention. Int. J. Neuropsychopharmacol. 10, 449 10.1017/S146114570600705X [DOI] [PMC free article] [PubMed] [Google Scholar]
  106. Salisbury A. L., Ponder K. L., Padbury J. F., Lester B. M. (2009). Fetal effects of psychoactive drugs. Clin. Perinatol. 36, 595 10.1016/j.clp.2009.06.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  107. Sasaki-Adams D. M., Kelley A. E. (2001). Serotonin-dopamine interactions in the control of conditioned reinforcement and motor behavior. Neuropsychopharmacology 25, 440–452 10.1016/S0893-133X(01)00240-8 [DOI] [PubMed] [Google Scholar]
  108. Schmitt J. A., Kruizinga M. J., Riedel W. J. (2001). Non-serotonergic pharmacological profiles and associated cognitive effects of serotonin reuptake inhibitors. J. Psychopharmacol. 15, 173–179 10.1177/026988110101500304 [DOI] [PubMed] [Google Scholar]
  109. Schmitt J. A. J., Jorissen B. L., Sobczak S., van Boxtel M. P. J., Hogervorst E., Deutz N. E. P., et al. (2000). Tryptophan depletion impairs memory consolidation but improves focussed attention in healthy young volunteers. J. Psychopharmacol. 14, 21–29 10.1177/026988110001400102 [DOI] [PubMed] [Google Scholar]
  110. Schmitt J. A. J., Wingen M., Ramaekers J. G., Evers E. A. T., Riedel W. J. (2006). Serotonin and human cognitive performance. Curr. Pharm. Des. 12, 2473–2486 10.2174/138161206777698909 [DOI] [PubMed] [Google Scholar]
  111. Schonfeld A. M., Paley B., Frankel F., O'Connor M. J. (2006). Executive functioning predicts social skills following prenatal alcohol exposure. Child Neuropsychol. 12, 439–452 10.1080/09297040600611338 [DOI] [PubMed] [Google Scholar]
  112. Schruers K., Esquivel G., van Duinen M., Wichers M., Kenis G., Colasanti A., et al. (2011). Genetic moderation of CO2-induced fear by 5-HTTLPR genotype. J. Psychopharmacol. 25, 37–42 10.1177/0269881110372543 [DOI] [PubMed] [Google Scholar]
  113. Shirtcliff E. A., Essex M. J. (2008). Concurrent and longitudinal associations of basal and diurnal cortisol with mental health symptoms in early adolescence. Dev. Psychobiol. 50, 690–703 10.1002/dev.20336 [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. Siepmann M., Grossmann J., Mück-Weymann M., Kirch W. (2003). Effects of sertraline on autonomic and cognitive functions in healthy volunteers. Psychopharmacology (Berl.) 168, 293–298 10.1007/s00213-003-1448-4 [DOI] [PubMed] [Google Scholar]
  115. Simpson K. L., Weaver K. J., de Villers-Sidani E., Lu J. Y., Cai Z., Pang Y., et al. (2011). Perinatal antidepressant exposure alters cortical network function in rodents. Proc. Natl. Acad. Sci. U.S.A. 108, 18465–18470 10.1073/pnas.1109353108 [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. Strobel A., Dreisbach G., Müller J., Goschke T., Brocke B., Lesch K. P. (2007). Genetic variation of serotonin function and cognitive control. J. Cogn. Neurosci. 19, 1923–1931 10.1162/jocn.2007.19.12.1923 [DOI] [PubMed] [Google Scholar]
  117. Taghavi M. R., Neshat-Doost H. T., Moradi A. R., Yule W., Dalgleish T. (1999). Biases in visual attention in children and adolescents with clinical anxiety and mixed anxiety-depression. J. Abnorm. Child Psychol. 27, 215–223 10.1023/A:1021952407074 [DOI] [PubMed] [Google Scholar]
  118. Taylor S. E., Way B. M., Welch W. T., Hilmert C. J., Lehman B. J., Eisenberger N. I. (2006). Early family environment, current adversity, the serotonin transporter promoter polymorphism, and depressive symptomatology. Biol. Psychiatry 60, 671–676 10.1016/j.biopsych.2006.04.019 [DOI] [PubMed] [Google Scholar]
  119. Valluzzi J. A., Chan K. H. (2007). Effects of fluoxetine on hippocampal-dependent and hippocampal-independent learning tasks. Behav. Pharmacol. 18, 507–513 10.1097/FBP.0b013e3282ee2a91 [DOI] [PubMed] [Google Scholar]
  120. van Ijzendoorn M. H., Belsky J., Bakermans-Kranenburg M. J. (2012). Serotonin transporter genotype 5HTTLPR as a marker of differential susceptibility? A meta-analysis of child and adolescent gene-by-environment studies. Transl. Psychiatry 2:e147 10.1038/tp.2012.73 [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Varnäs K., Halldin C., Hall H. (2004). Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. Hum. Brain Mapp. 22, 246–260 10.1002/hbm.20035 [DOI] [PMC free article] [PubMed] [Google Scholar]
  122. Weikum W. M., Oberlander T. F., Hensch T. K., Werker J. F. (2012). Prenatal exposure to antidepressants and depressed maternal mood alter trajectory of infant speech perception. Proc. Natl. Acad. Sci. U.S.A. 109, 17221–17227 10.1073/pnas.1121263109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  123. Zanto T. P., Rubens M. T., Thangavel A., Gazzaley A. (2011). Causal role of the prefrontal cortex in top-down modulation of visual processing and working memory. Nat. Neurosci. 14, 656–661 10.1038/nn.2773 [DOI] [PMC free article] [PubMed] [Google Scholar]
  124. Zheng J., Xu D., Li K., Wang H., Shen P., Lin M., et al. (2011). Neonatal exposure to fluoxetine and fluvoxamine alteres spine density in mouse hippocampal CA1 pyramidal neurons. Int. J. Clin. Exp. Pathol. 4, 162 [PMC free article] [PubMed] [Google Scholar]

Articles from Frontiers in Cellular Neuroscience are provided here courtesy of Frontiers Media SA

RESOURCES